Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Anti-HIV lipopeptide vaccine (Primary) ; HIV DNA vaccine (Primary) ; HIV DNA vaccine (Primary) ; MVA HIV vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ANRS/INSERM VRI01; VRI01
- 29 Aug 2017 New trial record
- 26 Jul 2017 Primary endpoint (Proportion of IFN--ELISPOT responders at Wk30, aiming to discard strategies with 50% responders (M2L2, L2M2, D3L2 group)) has not been met as per the results presented at the 9th International AIDS Society Conference on HIV Science.
- 26 Jul 2017 Primary endpoint (Proportion of IFN--ELISPOT responders at Wk30, aiming to discard strategies with 50% responders (D3M2 group)) has been met as per the results presented at the 9th International AIDS Society Conference on HIV Science